Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Next Previous
Search
Trial Profile

A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEL 212 (Primary)
  • Indications Gout; Gouty arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms DISSOLVE I
  • Sponsors Selecta Biosciences

    • Most Recent Events

    • 07 Nov 2024 According to a Swedish Orphan Biovitrum media release, data from this study to be presented at ACR Convergence 2024.
    • 02 Jul 2024 According to a Selecta Biosciences media release, based on results of DISSOLVE I and II trials, the company has initiated a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212
    • 15 Jun 2024 Results of pooled analysis describing the combined efficacy and safety data for SEL-212 from the 6-month DISSOLVE-I & II studies, presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top